Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-VENETOCLAX` `DRUG-AZACITIDINE`

ID	`REG-VEN-AZA-AML`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ELN-AML-2022` `SRC-NCCN-AML-2025` `SRC-VIALE-A-DINARDO-2020`

Notes

Standard 1L for AML unfit for intensive 7+3 (VIALE-A: median OS 14.7 vs 9.6 mo for aza alone). TLS prophylaxis MANDATORY for first ramp cycle (5-week ramp not used in AML — accelerated 3-day ramp instead). Strong CYP3A4 inhibitor co-administration (azole prophylaxis) requires venetoclax dose reduction. STUB — requires clinical co-lead signoff before publication.

Used By

Indication

IND-AML-1L-VEN-AZA - IND-AML-1L-VEN-AZA
IND-MDS-HR-1L-VEN-AZA - IND-MDS-HR-1L-VEN-AZA